Short Squeeze On This Stock Imminent?逼空即将发生在这支股票？

Cassava Sciences, Inc.,（SAVA 10.38） a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

The positives for SAVA:

1. Alzheimer's, for example, has proven one of the hardest diseases to treat. At least 400 clinical trials of treatments for it have been conducted over the past 17 years, and not one candidate has shown enough of an impact to earn regulatory approval. Right now, the number of people across the world with Alzheimer's is estimated to be about 44 million, and that figure is expected to triple by 2050.Cassava Sciences' oral drug candidate sumifilam recently achieved a first in Alzheimer's studies by both decreasing levels of a dangerous protein associated with the disease and improving blood-brain barrier integrity (its ability to control molecular exchanges between the blood and the brain). Malfunctions in this mechanism have been recognized as a key factor in Alzheimer's disease. This month, Cassava released data from a phase 2b trial of sumifilam; the study tested two dose levels, and participants taking both showed significant improvements on both metrics. ---Motley Fool 11/18/20202. 

2. Number of hedge funds bought into this stock increased from 2 to 8 during Q3.

3. Only 22 million shares float and a big 23% of shares shorted.

4. Earning estimates: +56% this year, +176% next year.

5. 2077 May 21, 2021 12.5 Calls purchased, unusual big volume today.

6. Zacks Research rated #2 stock (Buy).

7. Technicals: It jumped 4.81 yesterday to historical high 12 yesterday and it pull back only 1.07 today. Stock is on verge of a major breakout over 12. Once this happen shorts buy back should squeeze price up big time. SAVA support is 9.5, resistance is 12. It may go up to 16 if squeeze happens.

临床阶段生物技术公司Cassava Sciences，Inc.（SAVA 10.38）开发用于治疗神经系统疾病的药物。其领先的候选治疗药物是小分子药物PTI-125，已完成2b期临床试验；候选诊断产品是SavaDx，一种基于血液的生物标志物/诊断阿尔茨海默氏病。该公司原名为Pain Therapeutics，Inc.，并于2019年3月更名为Cassava Sciences，Inc.。Cassava Sciences，Inc.成立于1998年，总部位于德克萨斯州奥斯汀。

SAVA的优势：

 1. "阿尔茨海默氏病已被证明是最难治疗的疾病之一。在过去的17年中，至少进行了400次有关该药物治疗的临床试验，而且没有一位候选药显示出足够的影响力来获得监管部门的批准。目前，全世界患有阿尔茨海默氏症的人数估计约为4400万人，预计到2050年，这个数字将增加两倍。与疾病相关的危险蛋白，并改善血脑屏障的完整性（控制血液与大脑之间分子交换的能力）。该机制的功能障碍已被认为是阿尔茨海默氏病的关键因素。本月，SAVA发布了sumifilam 2b期试验的数据；该研究测试了两种剂量水平，服用两种剂量的参与者在两种指标上均显示出明显的改善。" --- Motley Fool 11/18/20202。

 2.在第三季度，购买该SAVA的对冲基金数量从2增加到8。

3.只有2200万股流通股，而23％的股票被卖空。

 4.收益估算：今年+ 56％，明年+ 176％。

 5. 2077 2021年5月21日12.5看涨期权倍购买，今天的交易量异常大。

 6. Zacks Research将其评为＃2股票（买入级别）。

 7.技术分析：昨天SAVA跳升了4.81，至昨天的历史高点12.99，今天仅回落了1.07。股票看来准备突破12。一旦发生这种情况，空头回购应该会推动价格飙升。 SAVA支撑是9.5，阻力是12。如果逼空发生，它可能会上升到16。